Is the CSL (ASX:CSL) share price on the road to recovery?

The CSL (ASX:CSL) share price has rebounded since hitting a 52-week low in early March. Are CSL shares finally on the road to recovery?
The post Is the CSL (ASX:CSL) share price on the road to recovery? appeared first on The Motley Fool Australia. –

A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies

The CSL Limited (ASX: CSL) share price has rebounded strongly since hitting a 52-week low of $242.00 in early March. The company is pushing forward with its locally manufactured COVID-19 vaccine rollout and implementing initiatives to restore plasma collections levels.

By yesterday’s market close, the global biotech’s shares finished the day 1.4% higher at $269.83.

With the latest developments, is the CSL share price finally on the road to recovery? Let’s take a look at what’s been happening for the biotech giant.

Vaccine update

Investors have buying CSL shares ahead of renewed optimism that the worst is behind the company.

According to the Australian Therapeutic Goods Administration (TGA), the first four batches of Melbourne-manufactured AstraZeneca COVID-19 vaccine have been released. This follows the TGA’s approval of the first 832,200 doses that were cleared Tuesday night. So far, almost 350,000 people in Australia have received a COVID-19 vaccination.

On Monday, the country moved to expand its COVID-19 vaccine eligibility to phase 1b group. This now includes elderly adults aged over 70 years, indigenous Australians, adults with pre-existing medical conditions, and other healthcare workers. However, there have been reports that general practitioner clinics have been overwhelmed with patients seeking the vaccine.

Despite the teething problems, it’s expected that, in the coming weeks, these concerns will ease. CSL plans to produce 1 million AstraZeneca COVID-19 vaccines each week up to a total of 50 million doses.

What about plasma collections?

While plasma collections have been heavily impacted by COVID-19, CSL has implemented a number of initiatives to incentivise blood donations. These include the use of social media influencers and the increase of donor compensation to as much as $700 per month. In addition, the company revealed plans to open up 12 new collection centres during the first half of FY21.

As world governments hastily inoculate their populations against COVID-19, experts predict that social norms will gradually return sometime in late 2021 to early 2022. Thus, if restrictions in the movement of people are lifted, CSL could find increasing numbers of blood donors returning to its collection centres.

CSL share price summary

The CSL share price has lost nearly 11% of its value when compared to this time last year. Year to date, the company’s shares are down by around 5%. CSL shares are also currently trading nearly 19% off their 52-week high of $332.68 reached in April last year.

On valuation grounds, CSL commands a market capitalisation of roughly $122.8 billion, with more than 455 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Is the CSL (ASX:CSL) share price on the road to recovery? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!